APA

Nakano K., Egashira K., Tada H., Kohjimoto Y., Hirouchi Y., Kitajima S., Endo Y., Li X. & Sunagawa K. (20070117). A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. : Journal of hypertension.

Chicago

Nakano Kaku, Egashira Kensuke, Tada Hideo, Kohjimoto Yoshiro, Hirouchi Yasuhiko, Kitajima Shun-ichi, Endo Yasuhisa, Li Xiao-Hang and Sunagawa Kenji. 20070117. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. : Journal of hypertension.

Harvard

Nakano K., Egashira K., Tada H., Kohjimoto Y., Hirouchi Y., Kitajima S., Endo Y., Li X. and Sunagawa K. (20070117). A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. : Journal of hypertension.

MLA

Nakano Kaku, Egashira Kensuke, Tada Hideo, Kohjimoto Yoshiro, Hirouchi Yasuhiko, Kitajima Shun-ichi, Endo Yasuhisa, Li Xiao-Hang and Sunagawa Kenji. A third-generation, long-acting, dihydropyridine calcium antagonist, azelnidipine, attenuates stent-associated neointimal formation in non-human primates. : Journal of hypertension. 20070117.